Welcome to our dedicated page for Philip Morris news (Ticker: PM), a resource for investors and traders seeking the latest updates and insights on Philip Morris stock.
Philip Morris International Inc. (PM) generates frequent news across corporate, regulatory, product and community topics, reflecting its role as an international consumer goods company focused on both cigarettes and smoke-free products. Company communications emphasize a transition toward a smoke-free future, with updates on heat-not-burn systems, nicotine pouches and e‑vapor products, as well as broader ambitions in wellness and healthcare.
News about PMI often covers its smoke-free strategy, including disclosures that smoke-free products account for a significant share of net revenues and are available in over 100 markets. Articles highlight the performance and regulatory status of brands such as IQOS heated tobacco products and ZYN nicotine pouches, including U.S. Food and Drug Administration marketing authorizations and Modified Risk Tobacco Product designations for certain products. Investors following PM can also expect coverage of major portfolio developments, such as the acquisition of Swedish Match and the integration of its oral tobacco and nicotine pouch offerings.
From a capital markets perspective, PMI news includes regular dividend declarations, earnings forecasts, and participation in investor conferences, as reported in regulatory news releases and Form 8‑K filings. The company also announces new bond issuances, credit facilities, and note redemptions, which are relevant to those tracking its balance sheet and funding strategy.
In the United States, PMI U.S. features prominently in news about manufacturing investments, job creation and community initiatives. Releases describe substantial U.S.-related investments in manufacturing capabilities, commercial rights and infrastructure, as well as philanthropic campaigns such as "Thanks for Giving" and the WeCare program, which support nonprofits across multiple regions. Motorsport sponsorships, including an expanded partnership with Scuderia Ferrari HP featuring ZYN branding at selected Formula 1 races, also appear in PMI’s news flow.
For investors, analysts and observers, the PM news page is a central place to review these developments, from smoke-free product milestones and regulatory decisions to financing transactions, organizational changes and community engagement efforts.
Philip Morris International (NYSE: PM) has declared a regular quarterly dividend of $1.35 per common share, payable on April 10, 2025, to shareholders of record as of March 20, 2025. The ex-dividend date is March 20, 2025.
The company continues its transformation towards a smoke-free future, having invested over $14 billion since 2008 in developing and commercializing smoke-free products. Following the acquisition of Swedish Match, PMI's portfolio is led by IQOS and ZYN brands. As of December 31, 2024, PMI's smoke-free products were available in 95 markets, with an estimated 38.6 million adult users worldwide. The smoke-free business contributed approximately 39% of PMI's total full-year 2024 net revenues.
Philip Morris International (PM) reaffirms its 2025 full-year forecast during the CAGNY Conference presentation. The company expects reported diluted EPS of $6.55 to $6.68, with adjusted diluted EPS of $7.04 - $7.17, representing a 7.2% to 9.1% increase versus 2024.
The presentation highlights PMI's decade-long progress toward a smoke-free future and its successful smoke-free brands. The company's smoke-free products are now available in 95 markets, with approximately 38.6 million adult users. Smoke-free business accounted for 39% of PMI's total full-year 2024 net revenues.
Since 2008, PMI has invested over $14 billion in developing and commercializing smoke-free products. The company's portfolio expansion includes the acquisition of Swedish Match, creating a global smoke-free champion led by IQOS and ZYN brands.
Philip Morris International (NYSE: PM) has announced its participation in the 2025 CAGNY Conference, where CEO Jacek Olczak and CFO Emmanuel Babeau will present on February 19, 2025. The presentation will be accessible via live audio webcast at 1:00 p.m. ET.
The company highlights its transformation towards a smoke-free future, having invested over $14 billion since 2008 in developing and commercializing smoke-free products. As of December 31, 2024, these products were available in 95 markets, with an estimated 38.6 million adult users worldwide. The smoke-free business generated approximately 39% of PMI's total full-year 2024 net revenues.
Following its acquisition of Swedish Match, PMI has strengthened its position in the smoke-free segment with brands like IQOS and ZYN. The company has received FDA authorization for marketing Swedish Match's General snus and ZYN nicotine pouches, as well as versions of IQOS devices and consumables.
Philip Morris International (PM) reported strong 2024 results with adjusted diluted EPS of $6.57, representing 9.3% growth (15.6% currency-neutral). The smoke-free business showed remarkable performance with net revenues increasing by 14.2% and gross profit up 18.7% for the full year.
Key highlights include smoke-free product shipments exceeding 40 billion units quarterly for the first time, with the segment accounting for 40% of total net revenues. The company reached 38.6 million estimated adult users of smoke-free products (up 5.3 million from 2023) across 95 markets. IQOS strengthened its position as the second-largest nicotine brand, while ZYN nicotine pouches showed significant growth, particularly in the U.S.
For 2025, PMI forecasts reported diluted EPS of $6.55-$6.68, with adjusted diluted EPS growth of 7.2-9.1%. The company expects total shipment volume growth up to 2%, driven by smoke-free products growth of 12-14%, and organic net revenue growth of 6-8%.
Philip Morris International (NYSE: PM) has announced it will host a live audio webcast to discuss its 2024 Fourth-Quarter and Full-Year financial results on Thursday, February 6, 2025, at 9:00 a.m. ET. The financial results will be released at approximately 7:00 a.m. ET the same day.
The webcast will feature CEO Jacek Olczak and CFO Emmanuel Babeau, including a Q&A session with investors. The listen-only event will be accessible via PMI's website and Investor Relations App, with recordings available until March 7, 2025.
As of June 30, 2024, PMI's smoke-free products were available in 90 markets, with an estimated 36.5 million adult users worldwide. The smoke-free business represented approximately 38% of PMI's total first-nine months 2024 net revenues. Since 2008, PMI has invested over $12.5 billion in developing smoke-free products, including the acquisition of Swedish Match in 2022, creating a global smoke-free portfolio led by IQOS and ZYN brands.
Philip Morris International (NYSE: PM) commissioned a multinational survey revealing strong public belief in innovation's potential to address critical issues. The survey, conducted by Povaddo across 10 countries, shows that 76% of people are excited about technology's opportunities, while 74% agree that debate on innovations is polarized.
Key findings include that 71% believe innovation can enable vaccine development, and 62% think it can ensure affordable healthcare. However, only 49% believe in innovation's capacity to reduce smoking rates. The survey highlights significant challenges, with 80% of respondents citing misinformation as a barrier to progress, and 64% worried about the rapid pace of technological change.
Citizens strongly support government action, with 90% emphasizing the importance of ensuring public access to accurate information and establishing clear regulations. Additionally, 87% want governments to tackle misinformation, and 83% support public-private sector collaboration.
Philip Morris International (NYSE: PM) announced that the FDA has authorized all ZYN nicotine pouch products, making ZYN the first and only authorized nicotine pouch in the United States. The authorization covers 20 different products across 10 flavors (Cool Mint, Peppermint, Spearmint, Wintergreen, Citrus, Coffee, Cinnamon, Smooth, Chill, and Menthol) in both 3mg and 6mg strengths.
The FDA's decision recognizes ZYN's potential role in public health protection by providing alternatives to approximately 45 million Americans who regularly consume nicotine, including 30 million smokers. Swedish Match N.A., a PMI subsidiary, emphasizes responsible marketing practices, including age verification systems and restrictions to adults 21+. The company is also a member of the We Card Program and TruAge® to ensure strict age verification compliance.
Philip Morris International (NYSE: PM) has declared a regular quarterly dividend of $1.35 per common share, payable on January 13, 2025, to shareholders of record as of December 26, 2024. The company has invested over $12.5 billion since 2008 in developing smoke-free products, which now account for approximately 38% of total revenues in the first nine months of 2024. PMI's smoke-free products are available in 90 markets with an estimated 36.5 million adult users globally. The company's portfolio includes the IQOS and ZYN brands following its acquisition of Swedish Match, positioning PMI as a global smoke-free champion.
Philip Morris International (PMI) celebrates the 10th anniversary of IQOS, its leading smoke-free product. Since IQOS's launch in Japan in 2014, the country has seen a 46% decrease in cigarette-smoking prevalence, dropping from 19.6% to 10.6% in 2022. IQOS now generates over $10 billion of PMI's annual net revenues and is available in over 70 markets with 30.8 million adult users. Smoke-free products account for 38% of PMI's net revenues in Q3 2024, up from nearly zero in 2014. The company has invested over $12.5 billion in developing and commercializing smoke-free products since 2008.
The FDA has renewed the modified risk tobacco product (MRTP) authorization for eight General snus products from Swedish Match, a Philip Morris International (PM) affiliate. This renewal allows Swedish Match to market these products as lower-risk alternatives to cigarettes. The authorization was based on 330 scientific studies, including epidemiological research from Sweden, which has one of the world's lowest smoking rates. The products can be marketed with claims that using General snus instead of cigarettes reduces the risk of various tobacco-related diseases. This marks a significant milestone as PMI affiliates have now secured 13 of the 16 MRTP authorizations granted by the FDA.